New ATC codes 2020
| ATC code | ATC level name |
|---|---|
| S01XA27 | voretigene neparvovec |
| A02BC08 | vonoprazan |
| A02BD15 | vonoprazan, amoxicillin and metronidazole |
| A02BD14 | vonoprazan, amoxicillin and clarithromycin |
| S01AA28 | vancomycin |
| L04AA44 | upadacitinib |
| B02AB05 | ulinastatin |
| J05AX24 | tecovirimat |
| G04CA54 | tamsulosin and tadalafil |
| L01XX67 | tagraxofusp |
| P01BA07 | tafenoquine |
| A10BK06 | sotagliflozin |
| N06BA14 | solriamfetol |
| L04AA42 | siponimod |
| L01XX66 | selinexor |
| J01AA14 | sarecycline |
| C10BX17 | rosuvastatin and ramipril |
| C10BA07 | rosuvastatin and omega-3 fatty acids |
| C10BX16 | rosuvastatin and fimasartan |
| C10BA09 | rosuvastatin and fenofibrate |
| L04AC18 | risankizumab |
| D06AX15 | rifamycin |
| A07AA13 | rifamycin |
| R03BB08 | revefenacin |
| N05CD14 | remimazolam |
| L04AA43 | ravulizumab |
| A02BD13 | rabeprazole, amoxicillin and metronidazole |
| A02BD12 | rabeprazole, amoxicillin and clarithromycin |
| L01XE52 | quizartinib |
| J01GB14 | plazomicin |
| C09BX04 | perindopril, bisoprolol and amlodipine |
| A16AB19 | pegvaliase |
| V04CX09 | patent blue |
| B06AX 1) | Other hematological agents |
| H02CA02 | osilodrostat |
| L04AB07 | opinercept |
| J01AA15 | omadacycline |
| P02CX03 | moxidectin |
| A03FA09 | mosapride |
| V09IX13 | methionine (11C) |
| V04CX03 | methacholine |
| V04CX04 | mannitol |
| B03XA06 | luspatercept |
| J01XX12 | lefamulin |
| S01EE06 | latanoprostene bunod |
| S01EE51 | latanoprost and netarsudil |
| L01XE53 | larotrectinib |
| J05AH04 | laninamivir |
| J05AR27 | lamivudine, tenofovir disoproxil and dolutegravir |
| J05AR25 | lamivudine and dolutegravir |
| L01XX62 | ivosidenib |
| C09DX07 | irbesartan, amlodipine and hydrochlorothiazide |
| N07XX15 | inotersen |
| R03AL12 | indacaterol, glycopyrronium bromide and mometasone |
| R03AK14 | indacaterol and mometasone |
| L04AA41 | imlifidase |
| A03BB06 | homatropine methylbromide |
| V04CX06 | hexaminolevulinate |
| J05AP11 | grazoprevir |
| D11AA01 | glycopyrronium |
| L01XX63 | glasdegib |
| L01XE54 | gilteritinib |
| N02CD03 | fremanezumab |
| R03AL11 | formoterol, glycopyrronium bromide and budesonide |
| R03AL10 | formoterol and tiotropium bromide |
| V04CX02 | folic acid |
| C09DB09 | fimasartan and amlodipine |
| B03AA12 | ferrous sodium citrate |
| L01XE57 | fedratinib |
| J05AX27 | favipiravir |
| N06AX27 | esketamine 2) |
| J04AB06 | enviomycin |
| L01XE56 | entrectinib |
| L01XX64 | entinostat |
| J05AP10 | elbasvir |
| L03AX21 | elapegademase |
| H01CC03 | elagolix |
| V04CX07 | edrophonium |
| G01AF55 | econazole, combinations |
| L04AX08 | darvadstrocel |
| J05AR26 | darunavir and ritonavir |
| L02BB06 | darolutamide |
| J05AP58 | daclatasvir, asunaprevir and beclabuvir |
| B06AX01 | crizanlizumab |
| D03AX14 | Centella asiatica herba |
| L01XC33 | cemiplimab |
| V04CX08 | carbon monoxide |
| S01LA06 | brolucizumab |
| B01AF04 | betrixaban |
| C10AX15 | bempedoic acid |
| L01XX68 | belotecan |
| J05AX25 | baloxavir marboxil |
| C10BA08 | atorvastatin and omega-3 fatty acids |
| V03AF11 | arginine and lysine |
| C08CA51 | amlodipine and celecoxib |
| J05AX26 | amenamevir |
| L01XX65 | alpelisib |
| L01XE51 | acalabrutinib |
| V04CX05 | 13C-urea |
1) New 4th level
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
2) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.
Last updated: 2019-12-20